2. Academic Validation
  3. Pathophysiology of Ganglioside GM1 in Ischemic Stroke: Ganglioside GM1: A Critical Review

Pathophysiology of Ganglioside GM1 in Ischemic Stroke: Ganglioside GM1: A Critical Review

  • Cell Transplant. 2019 Jun;28(6):657-661. doi: 10.1177/0963689718822782.
Wenchao Zhang 1,  Paul R Krafft 2,  Tianlong Wang 3,  John H Zhang 4 5,  Li Li 6 7,  Jiping Tang 4 7
Affiliations

Affiliations

  • 1 1 Department of Anesthesiology, Beijing Jishuitan Hospital, People's Republic of China.
  • 2 2 Department of Neurological Surgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, USA.
  • 3 3 Department of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing, People's Republic of China.
  • 4 4 Department of Physiology & Pharmacology, Loma Linda University School of Medicine, USA.
  • 5 5 Department of Anesthesiology, Loma Linda University School of Medicine, USA.
  • 6 6 Department of Anesthesiology, Beijing Friendship Hospital, Capital Medical University, People's Republic of China.
  • 7 Both the authors contributed equally to this work.
PMID: 30666888 DOI: 10.1177/0963689718822782
Abstract

Ganglioside GM1 is a member of the ganglioside family which has been used in many countries and is thought of as a promising alternative treatment for preventing several neurological diseases, including cerebral ischemic injury. The therapeutic effects of GM1 have been proved both in neonates and in adults following ischemic brain damage; however, its clinical efficacy in patients with ischemic stroke is still uncertain. This review examines the recent knowledge of the neuroprotective properties of GM1 in ischemic stroke, collected in the past two decades. We conclude that GM1 may have potential for stroke treatment, although we need to be cautious in respect of its complications.

Keywords

Ganglioside GM1; monosialotetrahexosylganglioside; stroke.

Figures
Products